HR Execs on the Move

Tarsus Pharmaceuticals

www.tarsusrx.com

 
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tarsusrx.com
  • 15440 Laguna Canyon Road Suite 160
    Irvine, CA USA 92618
  • Phone: 949.409.9820

Executives

Name Title Contact Details
Jeff Farrow
Chief Financial Officer and Chief Strategy Officer Profile
Torrie Plata
Senior Director, Human Resources Profile
Jenny Scott
HR Director Profile
Leo Greenstein
Chief Financial Officer Profile
Leo Greenstein
Chief Financial Officer Profile

Similar Companies

Advanced Clinical Services

Advanced Clinical Services is a Deerfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neauvia North America

Our Focus Neauvia North America was established in 2012 and is headquartered in Raleigh, North Carolina. It is the U.S. subsidiary of Neauvia, a global aesthetics brand present in more than 50 countries. Neauvia’s global headquarters is located in Luga...

UDG Healthcare plc

UDG Healthcare plc, formerly United Drug, is a Dublin-based international company and partner to the healthcare industry, providing clinical, commercial, communication and packaging services.

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.

Medical Center Compounding

Medical Center Compounding is a Cleveland, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.